Medicare slashes Vantas payments in third quarter update

Why This Topic Matters

The update is relevant to practices that bill Medicare for urology and oncology drugs because it combines reimbursement changes with coverage and billing considerations that can affect payment and patient responsibility. It also highlights how local policy and miscellaneous coding issues may influence claim submission and revenue management.

Article Sections

1. Medicare fee update and Vantas payment change

   Introduces the quarterly Medicare drug fee update and the change affecting one prostate cancer medication. It also places the update alongside other Medicare pricing context for the quarter.

2. Draft local coverage policy for LHRH analogs

   Summarizes a draft carrier policy discussion involving comparative coverage of several prostate cancer drugs. It also addresses beneficiary billing and follow-up monitoring considerations at a broad level.

3. Billing for implantation, removal, and miscellaneous HCPCS reporting

   Covers the related procedure and miscellaneous billing references discussed for implant management. It notes the article’s focus on coding and claim-submission issues tied to the medication and its delivery method.

4. Common urology drugs with updated Medicare fees

   Presents a fee update table for multiple urology-related drugs included in the Medicare quarterly announcement. The table compares payment amounts across the two cited reporting periods.